FINWIRES · TerminalLIVE
FINWIRES

Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat

-- Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported first-quarter results above market estimates.

The company now anticipates adjusted earnings of $5.38 to $5.58 per share for 2026, including a $0.20 dilution related to the Exact Sciences purchase. The company previously expected adjusted EPS to come in between $5.55 and $5.80 for the year, while the current consensus on FactSet is for $5.60.

Abbott acquired Exact Sciences in March.

"The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year," Abbott Chief Executive Robert Ford said in a statement.

Comparable sales, which includes the prior and current year sales of Exact Sciences, are pegged to grow by 6.5% to 7.5% for 2026, according to the company.

Abbott's shares fell 4.1% in Thursday trade, taking its year-to-date loss to 22%.

For the three-month period ended March, the firm's adjusted EPS rose to $1.15 from $1.09 the year before, surpassing the Street's view for $1.14. Sales improved 7.8% to $11.16 billion, topping the average analyst estimate of nearly $11 billion. Comparable sales were up 3.7%.

Diagnostics sales rose 6.1% year over year to $2.18 billion, while the nutrition segment dropped 6% to $2.02 billion amid lower sales volume and pricing actions in the previous quarter, according to the company. Revenue in the established pharmaceuticals division climbed 13% to $1.43 billion.

Sales in the global medical devices business jumped 13% to $5.54 billion, led by gains of 17% each in rhythm management and electrophysiology, Abbott said. Within the segment, the company recorded double-digit growth in heart failure and diabetes care.

For the second quarter, Abbott forecasts adjusted EPS of $1.25 to $1.31, while the Street is looking for $1.36.

Price: $97.09, Change: $-4.43, Percent Change: -4.36%

相关文章

Asia

福特斯克公布第三财季铁矿石总出货量增长,维持2026财年业绩预期

根据周五提交给澳大利亚证券交易所的文件,福特斯克(Fortescue,ASX:FMG)公布,截至3月31日的第三季度,铁矿石总出货量为4840万湿吨(wmt)。 文件显示,该公司2025年同期(截至3月31日)的铁矿石出货量为4610万湿吨。 文件还显示,该季度矿石开采量从2025年同期的5550万湿吨增至5950万湿吨,矿石加工量也从4760万湿吨略微增至4780万湿吨。 该公司维持其2026财年铁矿石出货量1.95亿至2.05亿吨、能源资本支出约3亿美元、净运营资本支出约4亿美元的预期。

$ASX:FMG
Asia

福特斯克集团将投资6.8亿美元开发西澳大利亚绿色能源项目

根据周五提交给澳大利亚证券交易所的文件,福特斯克(Fortescue,ASX:FMG)董事会已批准投资6.8亿澳元,用于在西澳大利亚皮尔巴拉地区开发新的绿色能源基础设施,这是其总额达62亿澳元的脱碳计划的一部分。 文件显示,该公司将开发200兆瓦的皮尔巴拉绿色能源项目,预计将于2028年完工,并计划在2030年后实现数吉瓦的扩建。 文件还指出,到2028年,福特斯克此前宣布的绿色电网将包括1.2吉瓦的太阳能、600兆瓦的风能、4至5吉瓦时的电池储能以及620公里的输电线路。

$ASX:FMG
Research

研究警示:CFRA维持对Knight-Swift Transportation Holdings Inc.股票的卖出评级。

独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将KNX的12个月目标价上调13美元至47美元,基于2027年每股收益预期,计算得出远期市盈率为15.6倍,高于五年历史平均水平。我们认为,每股收益和市场复苏足以抵消利润率疲软和宏观经济不确定性带来的影响。我们将2026年每股收益预期上调0.10美元至1.76美元,2027年每股收益预期上调0.57美元至3.02美元。KNX已连续七个季度展现出运营上的进步,包括拖拉机利用率的提升、成本结构的显著改善以及规模优势和多元化品牌平台带来的收益。然而,该股的估值似乎过高,比五年平均远期市盈率高出46%。鉴于第一季度业绩疲软,这一溢价似乎难以令人信服:盈利同比下降,利润率依然低迷,营收仅增长1%。虽然我们预计 2026-2027 年每股收益将强劲增长,但这主要代表从低迷水平的反弹,而不是扩张到新的领域,我们预计短期内盈利不会恢复到 2021-2022 年的峰值水平。

$KNX